Rockefeller Capital Management L.P. Raises Stock Holdings in Stryker Corporation $SYK

Rockefeller Capital Management L.P. grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 13.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 85,579 shares of the medical technology company’s stock after buying an additional 10,037 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Stryker were worth $30,079,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Norges Bank bought a new position in Stryker during the 4th quarter worth approximately $1,822,272,000. Auto Owners Insurance Co boosted its stake in Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the period. Wellington Management Group LLP boosted its position in shares of Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares during the period. Corient Private Wealth LLC grew its stake in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after buying an additional 741,542 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SYK shares. Needham & Company LLC decreased their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Barclays lowered their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Evercore set a $355.00 target price on Stryker in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Stock Performance

NYSE:SYK opened at $304.64 on Tuesday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $313.12 and its 200 day simple moving average is $341.06. The firm has a market capitalization of $116.79 billion, a PE ratio of 35.26, a PEG ratio of 1.97 and a beta of 0.78. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s payout ratio is currently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.